to page content
to site navigation
The Resource Center has all the info you'll need From content to user feedback, the resource center has the information you need for every level of the entrepreneurial process.
The venture capital climate improved in RTP in the first quarter, but biotech companies are still competing for dollars. Several RTP companies saw venture capital investment for development of pharmaceutical products and medical technologies. Read more to learn about the venture capital climate.
Hatteras Venture Partners, a venture capital firm, will invest $20 million to $30 million in helping companies through first-in-man and preclinical studies. The firm expects to invest in 10 to 15 companies in the healthcare business.
A North Carolina startup is taking on the problem of counterfeit drugs. The company’s technology embeds a tiny tag into the medicine itself that allows for identification and authentication to fight fraudulent pharmaceuticals.
A startup company with a new way to make nanofibers sees many potential applications in the medical business. Xanofi has the technology to make strides in several industries, including the healthcare business.
At-the-market offerings are used for investing in other industries, but they are just starting to pick up in life science investing. Read more on what the healthcare business should know about ATM offerings.
Pharma reps at GSK are selling their products in a new way. The emphasis is more on communicating a drug's benefits and risks than trying to sell as much as possible. Read more about this change in approach to sales.
Pharmaceutical companies are trying to adapt their marketing to an increasingly digital world. To get a handle on this environment, one company has appointed a digital advisory board of marketers from other industries.
Regenerative medicine has come a long way in recent years, leading some venture capitalists to consider investing in it. The roadblock to investing in this field is not a lack of funds, but rather a lack of a clear explanation of regenerative medicine's commercial applications, says one former venture capitalist.
Investing in seed and startup companies is extremely risky: Angel investors typically realize about 85 percent of their total portfolio returns from 15 percent of their portfolio companies. Consequently, angels look only for companies that can grow rapidly. Entrepreneurs who pursue less aggressive growth are unlikely to attract angel investors.
An important voice in the angel investing world, Luis Villalobos has contributed a practical new term--"valuation divergence"--that focuses on a little understood fact of angel investing: Returns on investments in a company do not increase in direct proportion to the company's market valuation. Entrepreneurs and investors alike will benefit from a better understanding of this concept.
Want to get connected? Sign up to receive regular news, polls and updates from The Kauffman Foundation.